Cargando…
A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs
A prevalence threshold to define rare diseases is needed for orphan drug designation. Here, we propose a bottom-up approach to defining rare diseases for China, based on the minimum number of patients needed for the industry to make a reasonable profit on a new drug. To obtain this patient populatio...
Autores principales: | Cui, Yazhou, Han, Jinxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353681/ https://www.ncbi.nlm.nih.gov/pubmed/25757391 http://dx.doi.org/10.1186/s13023-015-0241-x |
Ejemplares similares
-
Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020) -
Principles for consistent value assessment and sustainable funding of orphan drugs in Europe
por: Gutierrez, Laura, et al.
Publicado: (2015) -
How to START? Four pillars to optimally begin your orphan drug development
por: Jonker, Anneliene Hechtelt, et al.
Publicado: (2023) -
Orphan devices: yesterday is history; tomorrow is mystery: towards a European orphan device directive?
por: Dooms, Marc M
Publicado: (2016) -
The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development
por: Heslop, Emma, et al.
Publicado: (2015)